Key result
Piscine myocarditis virus infects all monitored salmon seasites, with ~50% progressing to clinical cardiomyopathy syndrome.
Why the study?
The study investigated the development of infection with Piscine myocarditis virus and development of cardiomyopathy syndrome in farmed Atlantic salmon in Norway.
How does Piscine myocarditis virus (PMCV) infection progress to clinical cardiomyopathy syndrome (CMS) over the marine grow-out phase in farmed Atlantic salmon, and can RT-qPCR screening predict CMS outbreaks?
Cohort (n=12)
Yes
How does Piscine myocarditis virus (PMCV) infection progress to clinical cardiomyopathy syndrome (CMS) over the marine grow-out phase in farmed Atlantic salmon, and can RT-qPCR screening predict CMS outbreaks?
Answers are grounded in this paper and cite their sources.
This veterinary aquaculture cohort study demonstrates that Piscine myocarditis virus is ubiquitous across Norwegian salmon farms and can persist without clinical cardiomyopathy syndrome, meaning PCR screening must be combined with clinical health assessments and targeting of dead or moribund fish.
An epidemiological study was carried out in Norway in 2015-2018, investigating the development of infection with Piscine myocarditis virus (PMCV) and development of cardiomyopathy syndrome (CMS) in farmed Atlantic salmon. Cohorts from 12 sites were followed and sampled every month or every other month from sea transfer to slaughter. PMCV was detected at all sites and in all sampled cages, and fish in six sites developed clinical CMS. The initial infection happened between 1 and 7 months post-sea transfer, and the median time from infection with PMCV until outbreak of CMS was 6.5 months. Generally, fish from sites with CMS had higher viral titre and a higher prevalence of PMCV, compared to sites that did not develop clinical CMS. The virus persisted until the point of slaughter at most (11 out of 12) of the sites. The detection of PMCV in all sites suggests that PMCV is more widespread than previously known. Screening for PMCV as a tool to monitor impending outbreaks of CMS must be supported by observations of the health status of the fish and risk factors for development of disease.
No takes yet. Share an insight, caveat, or question.
Svendsen et al. (2019) conducted a cohort in Piscine myocarditis virus (PMCV) infection and cardiomyopathy syndrome (CMS) in farmed Atlantic salmon (Salmo salar L.) (n=12). Natural exposure to Piscine myocarditis virus (PMCV) monitored via monthly or bimonthly RT-qPCR and histopathology screening vs. Sites that did not develop clinical cardiomyopathy syndrome (CMS-negative sites, n=4) was evaluated on Detection of Piscine myocarditis virus (PMCV) by RT-qPCR and development of clinical cardiomyopathy syndrome (CMS) confirmed by RT-PCR and histopathology (p=<0.001). Piscine myocarditis virus was detected in 100% of 12 monitored salmon seasites (1-7 months post-sea transfer), with 50% (6/12) developing clinical cardiomyopathy syndrome after a median of 6.5 months.
Synapse has enriched 10 related papers. Consider them for comparative context: